Gmed stock price forecast analysts cite steady orthopedic device

Analysts cite steady orthopedic device demand and improving hospital procedure volumes, suggesting potential upside if Q2 earnings beat expectations. Watch for trading volume spikes as an early trend signal. Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Globus Medical, we've compiled three additional items you should look at: In the past year, GMED’s shares have risen 83.9% compared with the industry ’s 14.8% growth. The GMED stock price forecast reflects increased optimism due to MedTech innovation pipelines. This is fueled by year-over-year revenue growth of over 12%, with traders eyeing breakout potential above $64 as momentum indicators strengthen in weekly charts.